H eart failure (HF) constitutes a prevalent clinical syndrome caused by a variety of structural and functional cardiac diseases and a complex multisystemic pathophysiology. Despite large improvements in medical treatment and patient management during the past decades, HF is still associated with high morbidity and mortality. 1 Thus, strategies to improve risk prediction are of major relevance in this epidemiologically important group of patients. 2, 3 Assessment of biomarkers represents an attractive concept for risk stratification in clinical practice, which has successfully been realized by the implementation of natriuretic peptides in the risk assessment of patients with HF. 4 In this respect, identification of new markers reflecting different aspects of the underlying pathophysiologic process may enhance diagnostic assessment and may provide additional prognostic information complementary to that assessable with natriuretic peptides. 5 Fibroblast growth factor 23 (FGF-23) is a hormone mainly secreted by osteocytes and involved in phosphate homeostasis by promoting renal phosphate excretion and downregulation of 1,25-dihydroxyvitamin D 3 synthesis. 6 Circulating levels of FGF-23 progressively rise with decreasing renal function, a common condition among HF patients with detrimental effect on survival, most probably to maintain serum phosphate levels in physiological ranges. 7 However, a vast array of studies identified FGF-23 as a strong and independent cardiovascular risk factor beyond its involvement in renal function and vitamin D3 and phosphate metabolism most strikingly associated with new onset of HF and hospitalization because of HF. [8] [9] [10] [11] [12] Accordingly, experimental data showed that FGF-23 has direct hypertrophic effects on cardiomyocytes, which corresponds to in vivo data in humans linking elevated FGF-23 levels with cardiac remodeling. 11, [13] [14] [15] On the basis of the pathophysiological role of FGF-23 in cardiac remodeling and renal impairment, we hypothesized that FGF-23 may be a useful biomarker for progressing disease severity and outcome in HF, potentially suitable for refining risk prediction in this group of patients. To test this hypothesis, we analyzed circulating levels of FGF-23 in 511 patients presenting with proven HF with reduced ejection fraction (HFrEF) and in 469 patients with proven HF with a preserved ejection fraction (HFpEF), which were part of the LUdwigshafen Risk and Cardiovascular Health (LURIC) and further aimed to assess potential differences in the predictive value between both HF entities. It is notable that FGF-23 has already been shown to predict mortality in the total population of LURIC. 16 For external validation, we additionally measured FGF-23 in a second cohort of 321 patients with advanced HFrEF.
Methods

Study Population
Derivation Cohort (LURIC)
Study participants were prospectively enrolled as part of the LURIC study between July 1997 and January 2000 as previously reported in detail. 17 Diagnosis of HF was made in accordance with current guidelines of the European Society of Cardiology. 18 Patients were further classified into patients with HFrEF and patients with HFpEF. HFpEF was diagnosed based on recommendations of the Heart Failure and Echocardiography Associations of the European Society of Cardiology as previously described. 19, 20 Of a total of 3316 patients referred for elective coronary angiography, 1086 patients presented with signs and symptoms of HF, including 580 patients with HFrEF and 506 patients with HFpEF. Plasma levels of FGF-23 were available for 511 patients with HFrEF and 469 patients with HFpEF.
Replication Cohort (Medical University of Vienna)
For external validation, FGF-23 levels were measured in 321 patients with advanced HFrEF enrolled between July 2003 and September 2004 in Vienna. Patients were included according to the following criteria: (1) hospitalization because of cardiac decompensation, (2) New York Heart Association (NYHA) functional classification III or IV at the time of admission, and (3) a left ventricular ejection fraction (LVEF) of <40%.
Both studies comply with the ethical principles for medical research involving human subjects as stipulated in the Declaration of Helsinki and were approved by the Ethics Committee of the LURIC and the Ethics Committee of the Medical University of Vienna (VIENNA). All patients gave written informed consent to participate in the respective study.
Follow-Up and Study End Points
All-cause mortality and cardiovascular mortality were chosen as primary and secondary study end points, respectively. Mortality data were obtained from local registries, including revision of death certificates to classify into cardiovascular and noncardiovascular causes of death (derivation cohort). In the replication cohort, end points were assessed reviewing the national register of death (Statistics Austria).
Blood Sampling and Laboratory Analyses
Technical details for blood sampling and laboratory measurements are provided in the Data Supplement.
Statistical Analysis
Discrete data are presented as counts and percentages and continuous data as median and interquartile range (IQR). Differences between categorical data were analyzed using Mantel-Haenszel-Chi square test for linear association. Mann-Whitney U test and Kruskal-Wallis test were applied for comparison of continuous data between groups as appropriate. Spearman ρ correlation coefficient was used to assess correlations between FGF-23 and continuous variables. Univariate and multivariable Cox proportional hazard models were applied to analyze the influence of FGF-23 on mortality. In a first model (model 1), we adjusted for age, sex, body mass index, NYHA functional classification, N-terminal pro-B-type natriuretic peptide (NT-proBNP), LVEF (semiquantitative), estimated glomerular filtration rate (eGFR) using modification of diet in renal disease formula, coronary artery disease (CAD), hypertension, diabetes mellitus, chronic obstructive pulmonary disease, and atrial fibrillation. In a second model (model 2), we additionally adjusted for phosphate and 1,25-dihydroxyvitamin D 3 concentrations in the derivation cohort. Results were expressed as the hazard ratio (HR) for a 1-SD increase of FGF-23 with the respective 95% confidence intervals (CIs). Interactions between FGF-23 and all variables included in multivariable models were tested by entering interaction terms in the Cox proportional hazard regression models. Kaplan-Meier curves for tertiles of FGF-23 were plotted to visualize the effect of FGF-23 on survival and compared using Log-rank test. Harrell C-statistic was calculated to assess the discriminatory power of biomarkers. 21 The category-free net reclassification index and integrated discrimination increment were applied to examine an improvement in individual risk assessment of FGF-23. 22 Comparison between risk models with and without FGF-23 was analyzed using likelihood-ratio test. A P value of <0.05 (2-tailed) was considered statistically significant. Statistical analyses were performed using SPSS 20.0 (IBM) and STATA 11 (StataCorp).
Results
Patient Characteristics
Baseline characteristics for patients with HFrEF from both cohorts (LURIC and VIENNA) and associations with FGF-23 are shown in Table 1 . Patients with HFrEF (n=511) in the LURIC derivation cohort had a median age of 65.5 (IQR, 57.9-71.4) years and a median NT-proBNP concentration of 1330 (IQR, 504-2886) pg/mL; 78.7% (n=402) were men, and 30.7% (n=157) were in NYHA class III or IV. Patients in the VIENNA replication cohort (n=321) were markedly older with a median age of 75.0 (IQR, 63.0-82.0) years and had a higher median NT-proBNP concentration of 2305 (IQR, 1161-5153) pg/mL; 65.7% (n=211) were men, and almost all patients were in NYHA class III or IV (97.5%; n=313). FGF-23 was consistently associated with markers of HF severity and impaired renal function as indicated by positive correlations with higher NYHA class, NT-proBNP concentration, and creatinine and negative correlations with eGFR in both cohorts. Furthermore, FGF-23 showed a positive correlation with phosphate and a negative correlation with 1,25-dihydroxyvitamin D 3 in the LURIC cohort.
FGF-23 and Risk Prediction
LURIC (Derivation Cohort)
The median follow-up time in the LURIC cohort was 8.6 (IQR, 3.2-10.1) years. During this period, 285 (55.7%) patients with HFrEF died, including 204 (39.9%) cases of cardiovascular death. FGF-23 showed a strong effect on survival in univariate Cox regression with a crude HR per 1 SD of 1.55 (95% CI, 1.40-1.73; P<0.001) for all-cause mortality and a crude HR per 1 SD of 1.56 (95% CI, 1.38-1.76; P<0.001) for cardiovascular mortality in patients with HFrEF (Table 2) . Corresponding Kaplan-Meier curves according to tertiles of FGF-23 are shown in Figure 1A and 1B. After adjustment for clinical characteristics (model 1), FGF-23 remained a significant predictor of all-cause mortality with an adjusted HR per 1 SD of 1.30 (95% CI, 1.14-1.48) and an adjusted HR per 1 SD of 1.28 (95% CI, 1.10-1.50) for cardiovascular mortality ( Table 2) . Additional adjustment for phosphate and 1,25-dihydroxyvitamin D 3 (model 2) resulted in a further moderate attenuation of the predictive value of FGF-23 with an adjusted HR per 1 SD of 1.26 (95% CI, 1.10-1.45; P=0.001) for all-cause mortality and an adjusted HR per 1 SD of 1.26 (95% CI, 1.07-1.47; P=0.005) for cardiovascular mortality ( Table 2 ). Of note, renal function did not modify the predictive value of FGF-23 (for interaction, P=0.510 for eGFR and P=0.465 for creatinine). In addition, no differences in the predictive value of FGF-23 were observed between female and male sexes (for interaction, P=0.339). To explore a potential incremental prognostic value of a combined assessment of FGF-23 and NT-proBNP beyond that achievable with NT-proBNP alone, we stratified patients into 9 groups according to tertiles of both biomarkers (Figure 2 ). FGF-23 demonstrated a consistent increase in predictive value comparing the third to the first tertile in all 3 tertiles of NT-proBNP. Patients with the highest values for both biomarkers experienced a 4.3-fold (P<0.001) increased risk of all-cause mortality and a 4.5-fold (P<0.001) increased risk of cardiovascular mortality compared with patients in the lowest tertiles of NT-proBNP and FGF-23. Accordingly, combined measurement of FGF-23 and NT-proBNP (C-statistic: 0.63) demonstrated a slightly better discriminatory power compared with measurement of NT-proBNP alone (C-statistic: 0.61; for comparison, P<0.001; Table 3 ). An improvement in individual risk stratification with combined assessment of both biomarkers was confirmed by improvements of the net reclassification index with 39.6% and integrated discrimination increment with 0.049 (Table 3) . To analyze whether FGF-23 is suitable for risk prediction in HFpEF, we additionally assessed plasma levels in 469 patients with HFpEF. Univariate Cox regression showed a significantly lower predictive value of FGF-23 in HFpEF compared with HFrEF (for interaction, P=0.043) with a crude HR per 1 SD of 1.23 (95% CI, 1.10-1.39; P=0.001) for all-cause mortality and a crude HR per 1 SD of 1.21 (95% CI, 1.04-1.41; P=0.012) for cardiovascular mortality. However, after multivariable adjustment for clinical variables (model 1), FGF-23 was no longer associated with mortality with an adjusted HR per 1 SD of 1.12 (95% CI, 0.97-1.41, P=0.132) for all-cause mortality and an adjusted HR per 1 SD of 1.04 (95% CI, 0.86-1.26; P=0.684) for cardiovascular mortality, respectively.
VIENNA (Replication Cohort)
During a median follow-up time of 3.7 (IQR, 1.2-4.8) years, 180 (56.1%) patients died including 133 (41.4%) cases of cardiovascular death. FGF-23 predicted mortality in univariate Cox regression with a crude HR per 1 SD of 1.45 (95% CI, 1.25-2.70; P<0.001) and cardiovascular mortality with a crude HR per 1 SD of 1.46 (95% CI, 1.23-2.83; P<0.001). After multivariable adjustment for potential confounders (model 1), FGF-23 remained predictive for allcause mortality with an adjusted HR per 1 SD of 1.23 (95% CI, 1.02-1.60; P=0.027) and for cardiovascular mortality with an adjusted HR per 1 SD of 1.24 (95% CI, 1.0-1.66; P=0.046; Table 2 ). Kaplan-Meier curves showing survival and survival free of cardiovascular mortality for tertiles of FGF-23 are presented in Figure 1C and 1D. Again, no significant difference in the predictive value of FGF-23 was found between patients with impaired and preserved renal function (for interaction, P=0.240 for eGFR). Stratification in combined groups of FGF-23 and NT-proBNP tertiles showed the highest risk in patients with high FGF-23 and high NT-proBNP concentrations with an HR of 5.51 (95% CI, 3.09-9.84; P<0.001) for all-cause mortality and an HR of 4.87 (95% CI, 2.60-9.15) for cardiovascular mortality compared with patients with low concentrations of both biomarkers. Combined assessment of NT-proBNP and FGF-23 showed a moderate improvement of discriminatory power †Variables used for calculation of model 2 were not available in the replication cohort.
(C-statistic: 0.66 versus 0.64) and individual risk prediction (net reclassification index, 18.2%; integrated discrimination increment, 0.018) compared with measurement of NT-proBNP alone (P=0.003; Table 3 ).
Discussion
In this study, we evaluated FGF-23 as a potential biomarker for risk prediction in patients with HF in 2 different cohorts of patients. FGF-23 turned out to be a specific predictor of mortality in patients with HFrEF independent of traditional cardiovascular risk factors and comorbidities, whereas this association was not observed in patients with HFpEF. Of note, despite a consistent association of FGF-23 with impaired renal function, the predictive value of FGF-23 remained unaffected by eGFR or creatinine. Although FGF-23 has been extensively studied in patients with chronic kidney disease and the general population, prospective data in patients with HF are rare. Only 2 studies with limited numbers of participants assessed FGF-23 in this patient group to date: Plischke et al 23 demonstrated an independent prognostic value of FGF-23 for all-cause mortality in 99 consecutive outpatients with HFrEF during a median followup of 35 months. Gruson et al 24 showed similar results in 73 HFrEF patients with a follow-up time of 6 years. FGF-23 was the strongest predictor of mortality in a multivariable analysis, including age, BNP, LVEF, eGFR, phosphorus, calcium, and parathyroid hormone. The present analysis confirms and extends these preceding findings with robust statistical power, a long-term follow-up time, a comparison between patients with HFrEF and HFpEF, and external validation of results.
Findings from several population-based studies further support an association between FGF-23 and HF. The Atherosclerosis Risk In Communities (ARIC) study found an independent association between FGF-23 and incident CAD and cardiovascular mortality and incident HF with the strongest association observed for the latter end point in a large cohort of 11 638 participants aged 45 to 65 years. 9 The Cardiovascular Health Study (CHS), which comprised 3107 participants aged ≥65 years demonstrated similar results showing a particularly strong association between FGF-23 and incident HF. 11 Consistent results demonstrating an increased risk of new-onset HF and cardiovascular events are reported in further study populations, including patients with stable CAD and patients with chronic kidney disease. 8, 12 However, the present data support a relevant role of FGF-23 not only in development of HF but also in progression of HF.
Beyond the robust association between FGF-23 and development and progression of HF in clinical studies, several lines of evidence indicate a direct linkage between FGF-23 and cardiac remodeling: various clinical studies demonstrated an association between circulating FGF-23 concentrations and left ventricular hypertrophy. 13, 14, 23, 25 Faul et al 13 showed hypertrophic growth in isolated neonatal rat cardiomyocytes and activation of fetal gene programs responsible for cardiac hypertrophy after treatment with FGF-23 in vitro and in vivo. Further experimental studies are required to clarify the specific role of FGF-23 in progression of HF. In this respect, differences in the predictive value between patients with HFpEF and HFrEF found in the present analysis are of interest. Seiler et al 26 showed significantly higher concentrations of FGF-23 in patients with an LVEF of <40% compared with patients with an LVEF of ≥40% undergoing elective coronary angiography, which supports a specific association of FGF-23 with impaired left ventricular systolic function, although these data cannot prove causality. However, the study did not specifically include patients with HFrEF and HFpEF and may therefore not be generalized to patients with HF. With respect to diastolic function, Okamoto et al 27 did not find an association of FGF-23 with diastolic impairment in a cross-sectional study comprising 269 patients with HFpEF. Future population studies with a clear discrimination of HF entities and experimental studies investigating the exact pathophysiological mechanisms will be necessary to further elucidate the differential role of FGF-23 in HFrEF and HFpEF.
In addition to the potential role of FGF-23 in cardiac remodeling, its association with reduced renal function may be another link with poor outcome in patients with HF. Chronic kidney disease represents a major risk factor for development of cardiovascular diseases most strikingly associated with new-onset of HF. 28 Considering the role of FGF-23 as a marker of progressing renal impairment, it may represent a potential mechanism through which chronic kidney disease increases the risk of HF. In this study, FGF-23 strongly correlated with a marker of impaired renal function, a relationship consistently observed in a vast number of studies. 29 However, the predictive value of FGF-23 proved to be unaffected by renal function measured with eGFR and remained virtually unchanged comparing patients with eGFR of ≥90 and <90 mL/min per 1.73 m 2 (data not shown). Concurringly, Poelzl et al 30 showed an association of FGF-23 with severity and prognosis in patients with CHF without renal impairment. However, it still remains open whether the cardiovascular risk associated with FGF-23 is dependent on renal function, as outcome studies in the general population or patients with CAD have been inconsistent on this question. 9, 11, 31 Another mechanism linking FGF-23 to an increased risk in patients with HFrEF may be its humoral activity involved in phosphate and vitamin D homeostasis. FGF-23 levels increase in response to a high phosphate load either through an increased dietary intake or decreased renal excretion and promote reduction of 1,25-dihydroxyvitamin D 3 , the humoral active form of vitamin D. 32 Correspondingly, FGF-23 revealed a moderate correlation with phosphate and a stronger negative correlation with 1,25-dihydroxyvitamin D 3 . To date, hyperphosphatemia has been shown to be associated with incident HF and an elevated risk for cardiovascular events in the general population and patients with stable CAD. [29] [30] [31] [32] [33] [34] It is further associated with disease severity and outcome in HF. 35 Similarly, low levels of 1,25-dihydroxyvitamin D 3 are linked with increased mortality in HF and represent a significant cardiovascular risk factor. 36 Nevertheless, multivariable adjustment for both variables resulted in a weak attenuation of the predictive value of FGF-23 by ≈10% only and may therefore be of minor importance in this context.
Limitations
The association between FGF-23 and mortality in patients with HF was independent of relevant comorbidities in both cohorts and specific for HFrEF as shown in the derivation cohort. FGF-23 provided additional discriminatory and individual predictive value beyond NT-proBNP in the derivation cohort but not in the replication cohort. As a further limitation, measurement of NT-proBNP and FGF-23 at different time points may have affected their correlation. With respect to technical details of biomarker measurement, only 120 of the total 2974 LURIC samples have been measured in duplicates (Data Supplement). Therefore, the individual %CV for each individual sample cannot be determined, which involves the risk of incorrect values because of technical errors. However, none of the samples measured in FGF-23 in addition to model 2 † 23.9 (5.7 to 42.1) ‡ Integrated discrimination increment FGF-23 in addition to NT-proBNP 0.049 (0.03 to 0.067) 0.018 (0.013 to 0.032) FGF-23 in addition to model 1* 0.02 (0.008 to 0.033) 0.004 (0 to 0.011) FGF-23 in addition to model 2 † 0.016 (0.005 to 0.027) ‡ Improvement in the performance of risk assessment of FGF-23 in addition to NT-proBNP, multivariable model 1 and model 2. Comparison between risk models with and without FGF-23 was assessed using likelihood-ratio test. Metrics of discrimination and reclassification included Harrel's C-statistic, categoryfree net reclassification index, and integrated discrimination increment. AUC indicates area under the curve; FGF-23, fibroblast growth factor 23; and NT-proBNP, N-terminal pro-B-type natriuretic peptide.
*Model 1 was adjusted for age, sex, body mass index, New York Heart Association functional classification, NT-proBNP, systolic left ventricular function (semiquantitative), estimated glomerular filtration rate (modification of diet in renal disease), coronary artery disease, hypertension, diabetes mellitus, chronic obstructive pulmonary disease, and atrial fibrillation. †Model 2 was adjusted for model 1+phosphate and 1,25-dihydroxyvitamin D. ‡Variables used for calculation of model 2 were not available in the replication cohort.
duplicate had a %CV of >20%, and the expected proportion of incorrect measured samples may therefore be low with presumably minor effect on the results. Furthermore, long storage of samples may have influenced the measurement of FGF-23.
Conclusions
In conclusion, FGF-23 was found to be an independent and specific predictor of mortality in patients with HFrEF but not in patients with HFpEF. In addition, our results demonstrate a gain in prognostic value in addition to NT-proBNP, the current biomarker gold standard in HFrEF, which favors a combined testing of both biomarkers for an improved risk assessment in this relevant and vulnerable group of patients. The predictive value of FGF-23 was not affected by renal function, serum phosphate levels, and 1,25-dihydroxyvitamin D 3 concentrations. Future studies addressing the exact pathophysiological mechanism with cardiac remodeling as a possible link between FGF-23 and outcome in HFrEF are necessary to further elucidate the role of FGF-23 in HF.
